Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University, Naples, Italy.
Sobell Department of Motor Neuroscience and Movement Disorders, University College London (UCL) Institute of Neurology, London, United Kingdom.
Parkinsonism Relat Disord. 2014 Jul;20(7):772-5. doi: 10.1016/j.parkreldis.2014.03.016. Epub 2014 Mar 25.
Low serum uric acid (UA) has been consistently shown to be associated with increased risk of Parkinson's disease (PD), and to predict faster motor and cognitive decline in established PD. The aim of the present study is to evaluate the relationship between serum UA and non-motor symptoms (NMS) in de novo PD.
Serum UA was measured in consecutively recruited, early drug-naïve PD patients. Exclusion criteria were: treatment with UA modifying drugs; current smoking status; metabolic or cardiac morbidity. All patients completed the NMS Questionnaire (NMSQuest). The relationship between UA levels and NMSQuest domains was explored by logistic regression, subsequently adjusted for age, gender, disease duration (months since reported motor onset) UPDRS part III, H&Y scale, and MMSE. Regression analysis studied the overall relationship between UA levels and total NMS score, and was subsequently adjusted for age, gender, disease duration UPDRS part III, H&Y scale and MMSE.
Eighty PD patients were recruited. At logistic regression, higher UA levels were related to lower involvement of Attention/Memory (p = 0.004), Cardiovascular (0.009) and Sleep (p = 0.028) domains of NMSQuest. UA levels showed a significant negative correlation with total NMSQuest score at regression analysis (p = 0.001; Adjusted R-squared = 0.319).
The present study investigated, for the first time, the relationship between NMSQuest and UA in de novo PD. Lower UA was related to higher NMSQuest total score and in particular to Attention/Memory, Cardiovascular and Sleep domains. Thus, UA seems to be a major candidate to be a valuable biomarker of such early features of PD as NMS.
低血清尿酸（UA）一直与帕金森病（PD）风险增加相关，并可预测已确诊 PD 患者的运动和认知功能下降更快。本研究旨在评估血清 UA 与新发 PD 患者非运动症状（NMS）之间的关系。
连续招募初治、药物未治疗的早期 PD 患者，并测量其血清 UA。排除标准为：使用 UA 调节剂治疗；当前吸烟状况；代谢或心脏疾病。所有患者均完成了非运动症状问卷（NMSQuest）。通过逻辑回归探讨 UA 水平与 NMSQuest 各领域之间的关系，随后根据年龄、性别、疾病持续时间（自报告运动起始后的月数）、UPDRS 第三部分、H&Y 量表和 MMSE 进行调整。回归分析研究了 UA 水平与总 NMS 评分之间的整体关系，并随后根据年龄、性别、疾病持续时间、UPDRS 第三部分、H&Y 量表和 MMSE 进行了调整。
共纳入 80 例 PD 患者。逻辑回归显示，UA 水平较高与注意力/记忆（p=0.004）、心血管（p=0.009）和睡眠（p=0.028）NMSQuest 领域的受累程度较低相关。回归分析显示，UA 水平与 NMSQuest 总分呈显著负相关（p=0.001；调整后的 R 平方=0.319）。
本研究首次探讨了新发 PD 患者 NMSQuest 与 UA 之间的关系。较低的 UA 与较高的 NMSQuest 总分相关，特别是与注意力/记忆、心血管和睡眠领域相关。因此，UA 似乎是 PD 早期 NMS 等特征的一个有价值的生物标志物。
